Sagimet Biosciences Inc. terminated its At-the-Market (ATM) equity offering program with Leerink Partners LLC effective September 30, 2026. The company also issued a press release announcing positive 52-week results from the Phase 3 ASC40-304 open-label extension clinical trial of denifanstat in patients with moderate to severe acne vulgaris, conducted by license partner Ascletis BioScience Co. Ltd. in China. Denifanstat demonstrated sustained efficacy and safety over 52 weeks, supporting the upcoming U.S. AURORA Phase 3 trial expected to begin patient screening in October 2026. Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors for metabolic and dermatological conditions.
